@prefix : <http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraine> .
@prefix dc: <http://purl.org/dc/elements/1.1/> .
@prefix mp: <http://purl.org/mp/> .
@prefix oa: <http://www.w3.org/ns/oa#> .
@prefix obo: <http://purl.obolibrary.org/obo/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xml: <http://www.w3.org/XML/1998/namespace> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix core: <http://purl.obolibrary.org/obo/uberon/core#> .
@prefix foaf: <http://xmlns.com/foaf/0.1/> .
@prefix pato: <http://purl.obolibrary.org/obo/pato#> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix core1: <http://purl.obolibrary.org/obo/core#> .
@prefix terms: <http://purl.org/dc/terms/> .
@prefix uberon: <http://purl.obolibrary.org/obo/uberon#> .
@prefix subsets: <http://purl.obolibrary.org/obo/ro/subsets#> .
@prefix oboInOwl: <http://www.geneontology.org/formats/oboInOwl#> .
@prefix OpenPVSignal: <http://purl.org/OpenPVSignal/OpenPVSignal.owl#> .
@base <http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraine> .

<http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraine> rdf:type owl:Ontology ;
                                                                  owl:imports <http://purl.org/OpenPVSignal/OpenPVSignal.owl> ,
                                                                              mp: ;
                                                                  rdfs:isDefinedBy "https://apps.who.int/iris/handle/10665/255501/"^^xsd:anyURI ;
                                                                  rdfs:label "Golimumab and Migraine"^^xsd:Literal ;
                                                                  owl:versionInfo "draft-v0.95-20211109"@en .

#################################################################
#    Object Properties
#################################################################

###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element
OpenPVSignal:Free_text_reporting_element rdf:type owl:ObjectProperty .


###  http://purl.org/mp/references
mp:references rdf:type owl:ObjectProperty .


#################################################################
#    Individuals
#################################################################

###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineConclusionContent
:ConclusionContent rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Conclusion ;
                   OpenPVSignal:has_content "In summary, there are 20 reports associating migraine with the use of golimumab. Golimumab was the only drug suspected in 15 of the 20 cases. Although there are alternative explanations such as adalimumab in two reports and the episodic recurrence of migraine in three other reports, the use of golimumab in association with migraine appears to be a signal. Time to onset is consistent with a drug induced effect. Dechallenge is supportive of a drug association but for a drug which is administered periodically, this is not compelling evidence. Migraine is mentioned in the product information of two other TNF-α inhibitors and for one of these drugs as well as an additional TNF-α inhibitor, there are significant reports of the association in Vigibase®. Finally, TNF-α is known to be involved in migraine so a mechanism for the involvement of TNF-α inhibitors in the development of migraine is a possibility." ;
                   rdfs:label "Conclusion content" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineDiscussionContent
:DiscussionContent rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Discussion ;
                   mp:references :Ref.2 ,
                                 :Ref.5 ,
                                 :Ref.6 ;
                   OpenPVSignal:has_content """Case reports in Vigibase® suggest that there is a possible signal for the association of golimumab and migraine. Golimumab was the only drug suspected in 15 of the 20 cases. There were other drugs suspected in the remaining five cases and in two of those, adalimumab was also a suspected drug. It could be considered a more likely cause as migraine is a known reaction to this drug. None of the other suspected drugs appear to be a more likely cause than golimumab and in Case 1, the temporal association appears better with golimumab than pandemic influenza vaccine. In Case 19, however, the patient recovered after hydromorphone was withdrawn while golimumab was probably continued. This suggests that hydromorphone is a more likely cause.
Time to onset was reported in five of the reports and ranged from the same day the drug was administered to eight months (median four weeks). Two other reports appeared to indicate that onset was within a month. This would appear consistent with a drug induced effect.
The outcome of the migraine was stated in nine reports. Six of these patients were reported as recovered and the remaining three patients had not recovered. In the six cases with recovery, golimumab was withdrawn in five cases and the fate of the drug was unclear in the other case. This last case is Case 19, mentioned above, in which hydromorphone appears a more likely cause. In the three cases where the patients had not recovered, the drug was withdrawn in two cases and continued in the other case. Dechallenge is usually considered as good evidence of drug association but for a drug which is administered periodically (monthly in this series), this is not necessarily supportive.
As noted above, there are no reports in the literature which link TNF-α inhibitors with migraine but this reaction is listed as common in the product literature for adalimumab and the product information for another TNF-α inhibitor, certolizumab, indicates that headache, including migraine, is a common reaction. In Vigibase®, there are 785 reports of migraine in association with etanercept, 683 with adalimumab, 224 with infliximab and 65 with certolizumab. This information raises the possibility that migraine may be a class effect of TNF-α inhibitors. It is known that activation in the trigeminal nucleus results in the release of vasoactive neuropeptides, particularly calcitonin gene-related peptide (CGRP) and that CGRP receptor antagonists have been shown to be effective in the treatment of migraine.2 Durham noted that TNF-α was implicated in migraine as have a number of others including Robbins and Maides, and Durham further noted that several findings in migraineurs support a role of CGRP in migraine and that TNF-α can stimulate CGRP transcription.5,6 These findings suggest that TNF-α inhibitors may be protective against migraine but the involvement of TNF-α in migraine does indicate that a mechanism for the involvement of TNF-α inhibitors in the development of migraine is a possibility""" ;
                   rdfs:label "Discussion content" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineDosageOfGolimumab
:DosageOfGolimumab rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Dosage ;
                   OpenPVSignal:refers_to_drug :golimumab ;
                   OpenPVSignal:refers_to_interval_between_administrations :monthly ;
                   OpenPVSignal:has_dosage_unit "mg"^^xsd:string ;
                   OpenPVSignal:has_value 50 ;
                   OpenPVSignal:refers_to_dose_value "50 mg" ;
                   rdfs:label "Dosage of Golimumab" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineDr_Ian_Boyd
:Dr_Ian_Boyd rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Author ;
             OpenPVSignal:has_affiliation "Australia" ;
             OpenPVSignal:has_first_name "Ian" ;
             OpenPVSignal:has_last_name "Boyd" ;
             rdfs:label "Dr Ian Boyd" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineGolimumabAndAutoimmunieProcess
:GolimumabAndAutoimmunieProcess rdf:type owl:NamedIndividual ,
                                         OpenPVSignal:Warning_Information ;
                                OpenPVSignal:refers_to_adverse_effect :lupus-likeSyndrome ;
                                OpenPVSignal:refers_to_drug :golimumab ;
                                rdfs:label "Golimumab and autoimmunie process" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineGolimumabAndBalanceDisorders
:GolimumabAndBalanceDisorders rdf:type owl:NamedIndividual ,
                                       OpenPVSignal:Warning_Information ;
                              OpenPVSignal:refers_to_adverse_effect :disorders ;
                              OpenPVSignal:refers_to_drug :golimumab ;
                              rdfs:label "Golimumab and balance disorders" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineGolimumabAndCongestiveHeartFailure
:GolimumabAndCongestiveHeartFailure rdf:type owl:NamedIndividual ,
                                             OpenPVSignal:Warning_Information ;
                                    OpenPVSignal:refers_to_adverse_effect :congestiveHeartFailure ;
                                    OpenPVSignal:refers_to_drug :golimumab ;
                                    rdfs:label "Golimumab and congestive heart failure" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineGolimumabAndDemyelinatingDisorders
:GolimumabAndDemyelinatingDisorders rdf:type owl:NamedIndividual ,
                                             OpenPVSignal:Warning_Information ;
                                    OpenPVSignal:refers_to_adverse_effect :demyelinatingDisorders ;
                                    OpenPVSignal:refers_to_drug :golimumab ;
                                    rdfs:label "Golimumab and demyelinating disorders" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineGolimumabAndDizziness
:GolimumabAndDizziness rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Warning_Information ;
                       OpenPVSignal:refers_to_adverse_effect :dizziness ;
                       OpenPVSignal:refers_to_drug :golimumab ;
                       rdfs:label "Golimumab and dizziness" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineGolimumabAndDysgeusia
:GolimumabAndDysgeusia rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Warning_Information ;
                       OpenPVSignal:refers_to_adverse_effect :dysgeusia ;
                       OpenPVSignal:refers_to_drug :golimumab ;
                       rdfs:label "Golimumab and dysgeusia" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineGolimumabAndHaematologicalReactions
:GolimumabAndHaematologicalReactions rdf:type owl:NamedIndividual ,
                                              OpenPVSignal:Warning_Information ;
                                     OpenPVSignal:refers_to_adverse_effect :haematologicalReactions ;
                                     OpenPVSignal:refers_to_drug :golimumab ;
                                     rdfs:label "Golimumab and haematological reactions" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineGolimumabAndHeadache
:GolimumabAndHeadache rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Warning_Information ;
                      OpenPVSignal:refers_to_adverse_effect :headache ;
                      OpenPVSignal:refers_to_drug :golimumab ;
                      rdfs:label "Golimumab and headache" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineGolimumabAndHepatitisBVirusReactivation
:GolimumabAndHepatitisBVirusReactivation rdf:type owl:NamedIndividual ,
                                                  OpenPVSignal:Warning_Information ;
                                         OpenPVSignal:refers_to_adverse_effect :hepatitisBVirusReactivation ;
                                         OpenPVSignal:refers_to_drug :golimumab ;
                                         rdfs:label "Golimumab and hepatitis B virus reactivation" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineGolimumabAndLymphoma
:GolimumabAndLymphoma rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Warning_Information ;
                      OpenPVSignal:refers_to_adverse_effect :lymphoma ;
                      OpenPVSignal:refers_to_drug :golimumab ;
                      rdfs:label "Golimumab and lymphoma" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineGolimumabAndParaesthesia
:GolimumabAndParaesthesia rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Warning_Information ;
                          OpenPVSignal:refers_to_adverse_effect :paraesthesia ;
                          OpenPVSignal:refers_to_drug :golimumab ;
                          rdfs:label "Golimumab and paraesthesia" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineGolimumabAndSeriousInfections
:GolimumabAndSeriousInfections rdf:type owl:NamedIndividual ,
                                        OpenPVSignal:Warning_Information ;
                               OpenPVSignal:refers_to_adverse_effect :invasiveFungal ,
                                                                     :opportunisticInfections ,
                                                                     :pneumonia ,
                                                                     :sepsis ,
                                                                     :tuberculosis ;
                               OpenPVSignal:refers_to_drug :golimumab ;
                               rdfs:label "Golimumab and serious infections" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineGolimumab_and_Migraine
:Golimumab_and_Migraine rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Pharmacovigilance_Signal_Report ;
                        OpenPVSignal:refers_to_author :Dr_Ian_Boyd ;
                        OpenPVSignal:refers_to_signal :pvSignal ;
                        OpenPVSignal:has_creation_date "01/05/2015" ;
                        OpenPVSignal:has_overall_conclusion "causal association probable" ;
                        rdfs:label "Golimumab and Migraine" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineIntroduction_content
:Introduction_content rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Introduction ;
                      mp:references :Ref.1 ,
                                    :Ref.2 ;
                      OpenPVSignal:has_content "Golimumab is a human monoclonal antibody that forms high affinity, stable complexes with both the soluble and transmembrane bioactive forms of human tumour necrosis factor (TNF)-α, which prevents the binding of TNF-α to its receptors. It is indicated for the treatment of ulcerative colitis (UC), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and rheumatoid arthritis (RA) in combination with methotrexate (MTX). The most serious ADRs that have been reported for golimumab include serious infections (including sepsis, pneumonia, tuberculosis, invasive fungal and opportunistic infections), demyelinating disorders, lymphoma, hepatitis B virus reactivation, congestive heart failure, autoimmune processes (lupus-like syndrome) and haematological reactions. The adverse reactions which have been reported commonly or very commonly include infections and infestations such as upper respiratory tract infection, bacterial infections, lower respiratory tract infection, viral infections, bronchitis, sinusitis, superficial fungal infections, and abscess; immune system disorders such as allergic reactions and autoantibody positive; nervous system disorders such as dizziness, headache and paraesthesia; gastrointestinal disorders; skin and subcutaneous tissue disorders; general disorders and administration site conditions such as pyrexia, asthenia, and injection site reaction; depression, insomnia, increases in liver function tests, asthma, hypertension and anaemia.1 Migraine is the second most common form of headache, afflicting approximately 15% of women and 6% of men over a one year period. It is usually an episodic headache associated with certain features such as sensitivity to light, sound, or movement; nausea and vomiting often accompany the headache. A useful description of migraine is a benign and recurring syndrome of headache associated with other symptoms of neurological dysfunction in various admixtures.2" ;
                      rdfs:label "Introduction content" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineLiteratureAndLabelling
:LiteratureAndLabelling rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Literature_information ;
                        mp:references :Ref.3 ,
                                      :Ref.4 ;
                        OpenPVSignal:has_content """The product literature does not refer to migraine although it does refer to headache. The neurological reactions mentioned include dizziness, headache and
paraesthesia (common), balance disorders (uncommon) and demyelinating disorders (central and peripheral) and dysgeusia (rare). There are no reports in the literature which link migraine with golimumab. There are also no reports in the literature which link other TNF-α inhibitors with migraine but this reaction is listed as common in the product literature for adalimumab.3 In addition, the product information for another TNF- α inhibitor, certolizumab, indicates that headache, including migraine, is a common reaction.4
""" ;
                        rdfs:label "Literature and Labelling" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineMechanism_of_Golimumab
:Mechanism_of_Golimumab rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Mechanism ;
                        mp:references :Ref.1 ;
                        OpenPVSignal:has_content "Golimumab is a human monoclonal antibody that forms high affinity, stable complexes with both the soluble and transmembrane bioactive forms of human tumour necrosis factor (TNF)-α, which prevents the binding of TNF-α to its receptors." ;
                        rdfs:label "Mechanism of Golimumab" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineMigraine_and_adalimumab
:Migraine_and_adalimumab rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Structured_Product_Labels_information ,
                                  OpenPVSignal:Warning_Information ;
                         OpenPVSignal:refers_to_adverse_effect :migraine ;
                         OpenPVSignal:refers_to_drug :adalimumab ;
                         mp:references :Ref.5 ;
                         rdfs:label "Migraine and adalimumab" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineMigraine_and_certolizumab
:Migraine_and_certolizumab rdf:type owl:NamedIndividual ,
                                    OpenPVSignal:Structured_Product_Labels_information ,
                                    OpenPVSignal:Warning_Information ;
                           OpenPVSignal:refers_to_adverse_effect :headache ,
                                                                 :migraine ;
                           OpenPVSignal:refers_to_drug :certolizumab ;
                           mp:references :Ref.4 ;
                           rdfs:label "Migraine / headache and certolizumab" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineMigraine_pathology
:Migraine_pathology rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Free_text_reporting_element ;
                    OpenPVSignal:refers_to_adverse_effect :migraine ;
                    mp:references :Ref.2 ;
                    OpenPVSignal:has_content "Migraine is the second most common form of headache, afflicting approximately 15% of women and 6% of men over a one year period. It is usually an episodic headache associated with certain features such as sensitivity to light, sound, or movement; nausea and vomiting often accompany the headache. A useful description of migraine is a benign and recurring syndrome of headache associated with other symptoms of neurological dysfunction in various admixtures.2" ;
                    rdfs:label "Migraine pathophysiology" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineOverallReportsForAdalimumabAndMigraine
:OverallReportsForAdalimumabAndMigraine rdf:type owl:NamedIndividual ,
                                                 OpenPVSignal:Reports_group ;
                                        OpenPVSignal:refers_to_adverse_effect :migraine ;
                                        OpenPVSignal:refers_to_drug :adalimumab ;
                                        OpenPVSignal:has_count 683 ;
                                        OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                        rdfs:label "Overall reports for adalimumab and migraine" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineOverallReportsForCertolizumab
:OverallReportsForCertolizumab rdf:type owl:NamedIndividual ,
                                        OpenPVSignal:Reports_group ;
                               OpenPVSignal:refers_to_adverse_effect :migraine ;
                               OpenPVSignal:has_count 65 ;
                               OpenPVSignal:refers_to_database "WHO Vigibase" ;
                               rdfs:label "Overall reports for certolizumab and migraine" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineOverallReportsForEtanerceptAndMigraine
:OverallReportsForEtanerceptAndMigraine rdf:type owl:NamedIndividual ,
                                                 OpenPVSignal:Reports_group ;
                                        OpenPVSignal:refers_to_adverse_effect :migraine ;
                                        OpenPVSignal:refers_to_drug :etanercept ;
                                        OpenPVSignal:has_count 785 ;
                                        OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                        rdfs:label "Overall reports for etanercept and migraine" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineOverallReportsForInfiximabAndMigraine
:OverallReportsForInfiximabAndMigraine rdf:type owl:NamedIndividual ,
                                                OpenPVSignal:Reports_group ;
                                       OpenPVSignal:refers_to_adverse_effect :migraine ;
                                       OpenPVSignal:refers_to_drug :infliximab ;
                                       OpenPVSignal:has_count 224 ;
                                       OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                       rdfs:label "Overall reports for infiximab and migraine" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineOverallReportsWithGolimumabAndMigraine
:OverallReportsWithGolimumabAndMigraine rdf:type owl:NamedIndividual ,
                                                 OpenPVSignal:Reports_group ;
                                        OpenPVSignal:refers_to_adverse_effect :migraine ,
                                                                              :migraineAggravated ;
                                        OpenPVSignal:refers_to_drug :golimumab ;
                                        OpenPVSignal:has_count 20 ;
                                        OpenPVSignal:has_count_of_men 2 ;
                                        OpenPVSignal:has_count_of_women 18 ;
                                        OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                        rdfs:label "Overall reports without duplicates" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainePatient1
:Patient1 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 48 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 1" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainePatient10
:Patient10 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 10" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainePatient11
:Patient11 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 64 ;
           OpenPVSignal:has_gender "male" ;
           rdfs:label "Patient 11" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainePatient12
:Patient12 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 60 ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 12" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainePatient13
:Patient13 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 13" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainePatient14
:Patient14 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 14" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainePatient15
:Patient15 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 15" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainePatient16
:Patient16 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 16" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainePatient17
:Patient17 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 60 ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 17" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainePatient18
:Patient18 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 18" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainePatient19
:Patient19 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 65 ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 19" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainePatient2
:Patient2 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 55 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 2" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainePatient20
:Patient20 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 57 ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 20" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainePatient21
:Patient21 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 57 ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 21" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainePatient22
:Patient22 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 59 ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 22" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainePatient3
:Patient3 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 77 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 3" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainePatient4
:Patient4 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 4" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainePatient5
:Patient5 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 5" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainePatient6
:Patient6 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 6" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainePatient7
:Patient7 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 53 ;
          OpenPVSignal:has_gender "male" ;
          rdfs:label "Patient 7" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainePatient8
:Patient8 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 8" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainePatient9
:Patient9 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 37 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 9" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainePotentialMechanismOfInductionOfMigraineByGolimumab
:PotentialMechanismOfInductionOfMigraineByGolimumab rdf:type owl:NamedIndividual ,
                                                             OpenPVSignal:Adverse_Effect_Mechanism ;
                                                    OpenPVSignal:refers_to_adverse_effect :migraine ;
                                                    mp:references :Ref.2 ,
                                                                  :Ref.5 ,
                                                                  :Ref.6 ;
                                                    OpenPVSignal:has_content "It is known that activation in the trigeminal nucleus results in the release of vasoactive neuropeptides, particularly calcitonin gene-related peptide (CGRP) and that CGRP receptor antagonists have been shown to be effective in the treatment of migraine.2 Durham noted that TNF-α was implicated in migraine as have a number of others including Robbins and Maides, and Durham further noted that several findings in migraineurs support a role of CGRP in migraine and that TNF-α can stimulate CGRP transcription.5,6 These findings suggest that TNF-α inhibitors may be protective against migraine but the involvement of TNF-α in migraine does indicate that a mechanism for the involvement of TNF-α inhibitors in the development of migraine is a possibility." ;
                                                    rdfs:label "Potential mechanism of induction of migraine by TNF-a inhibitors" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineRef.1
:Ref.1 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "European Medicines Agency. Summary of product characteristics for Simponi. URL: http://www.ema. europa.eu/docs/en_GB/ document_library/EPAR_-_Product_ Information/human/000992/WC500052368. pdf. Accessed: 7 October 2014." ;
       rdfs:label "Ref.1" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineRef.2
:Ref.2 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, eds. Harrison’s Principles of Internal Medicine, 18th ed. McGraw Hill, New York, 2011." ;
       rdfs:label "Ref.2" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineRef.3
:Ref.3 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "European Medicines Agency. Summary of product characteristics for Humira. URL: http://www.ema. europa.eu/docs/en_GB/ document_library/EPAR_-_Product_ Information/human/000481/WC500050870. pdf. Accessed: 9 October 2014." ;
       rdfs:label "Ref.3" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineRef.4
:Ref.4 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "European Medicines Agency. Summary of product characteristics for Cimzia. URL: http://www.ema. europa.eu/docs/en_GB/ document_library/EPAR_-_Product_ Information/human/001037/ WC500069763. pdf. Accessed: 10 October 2014." ;
       rdfs:label "Ref.4" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineRef.5
:Ref.5 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Durham PL. Emerging Neural Theories of Migraine Pathogenesis: calcitonin gene-related peptide (CGRP) and migraine. Headache 2006; 46: S3-S8." ;
       rdfs:label "Ref.5" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineRef.6
:Ref.6 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Robbins L, Maides J. Practical pain management. The immune system and headache. URL: http://www. practicalpainmanagement.com/pain/headache/im mune-system-headache. Accessed: 10 November 2014." ;
       rdfs:label "Ref.6" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReport1
:Report1 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:has_free_text_reporting_element :infoForCase1 ;
         OpenPVSignal:refers_to_adverse_effect :coughing ,
                                               :eyePain ,
                                               :fever ,
                                               :headache ,
                                               :influenzaImmunisation ,
                                               :migraine ,
                                               :myalgia ,
                                               :rhinitis ;
         OpenPVSignal:refers_to_concomitant_drug :decongestants ,
                                                 :folicAcid ,
                                                 :meloxicam ,
                                                 :methotrexate ;
         OpenPVSignal:refers_to_patient :Patient1 ;
         OpenPVSignal:refers_to_primary_suspect_drug :golimumab ;
         OpenPVSignal:refers_to_secondary_suspect_drug <http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraine#A/H1N1InfluenzaPandemicVaccine> ;
         OpenPVSignal:refers_to_outcome_after_action "unknown" ;
         rdfs:label "Report 1" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReport10
:Report10 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :migraine ,
                                                :visualAbnormal ;
          OpenPVSignal:refers_to_patient :Patient10 ;
          OpenPVSignal:refers_to_primary_suspect_drug :golimumab ;
          OpenPVSignal:refers_to_outcome_after_action "unknown" ;
          rdfs:label "Report 10" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReport11
:Report11 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :jointFluidDrainage ,
                                                :malaise ,
                                                :migraine ;
          OpenPVSignal:refers_to_concomitant_drug :antihypertensives ,
                                                  :methotrexate ;
          OpenPVSignal:refers_to_patient :Patient11 ;
          OpenPVSignal:refers_to_primary_suspect_drug :golimumab ;
          OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
          rdfs:label "Report 11" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReport12
:Report12 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :migraine ;
          OpenPVSignal:refers_to_patient :Patient12 ;
          OpenPVSignal:refers_to_primary_suspect_drug :golimumab ;
          OpenPVSignal:refers_to_outcome_after_action "unknown" ;
          rdfs:label "Report 12" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReport13
:Report13 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :abdominalPain ,
                                                :allergicReaction ,
                                                :anxiety ,
                                                :asthma ,
                                                :haemorrhageNos ,
                                                :migraine ,
                                                :oedemaGeneralised ,
                                                :oedemaPeripheral ,
                                                :rhinitis ;
          OpenPVSignal:refers_to_concomitant_drug :betamethasone ,
                                                  :clonazepam ,
                                                  :folicAcid ,
                                                  :hydrochlorothiazide ,
                                                  :ibuprofen ,
                                                  :levothyroxine ,
                                                  :methotrexate ,
                                                  :salbutamol ,
                                                  :spironolactone ,
                                                  :zolpidem ;
          OpenPVSignal:refers_to_patient :Patient13 ;
          OpenPVSignal:refers_to_primary_suspect_drug :golimumab ;
          OpenPVSignal:refers_to_outcome_after_action "unknown" ;
          rdfs:label "Report 13" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReport14
:Report14 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :migraine ,
                                                :visionAbnormal ;
          OpenPVSignal:refers_to_patient :Patient14 ;
          OpenPVSignal:refers_to_primary_suspect_drug :golimumab ;
          OpenPVSignal:refers_to_outcome_after_action "unknown" ;
          rdfs:label "Report 14" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReport15
:Report15 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :giHaemorrhage ,
                                                :headache ,
                                                :hypertension ,
                                                :migraine ;
          OpenPVSignal:refers_to_patient :Patient15 ;
          OpenPVSignal:refers_to_primary_suspect_drug :golimumab ;
          OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
          rdfs:label "Report 15" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReport16
:Report16 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :dysphemia ,
                                                :hearingDecreased ,
                                                :migraine ,
                                                :visionAbnormal ;
          OpenPVSignal:refers_to_concomitant_drug :sulfasalazine ;
          OpenPVSignal:refers_to_patient :Patient16 ;
          OpenPVSignal:refers_to_primary_suspect_drug :golimumab ;
          OpenPVSignal:refers_to_outcome_after_action "unknown" ;
          rdfs:label "Report 16" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReport17
:Report17 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :bronchitis ,
                                                :dizziness ,
                                                :hypoaesthesia ,
                                                :migraine ,
                                                :paraesthesia ,
                                                :pharyngitis ,
                                                :visionAbnormal ;
          OpenPVSignal:refers_to_patient :Patient17 ;
          OpenPVSignal:refers_to_primary_suspect_drug :golimumab ;
          OpenPVSignal:refers_to_outcome_after_action "unknown" ;
          rdfs:label "Report 17" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReport18
:Report18 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :abdominalPain ,
                                                :migraine ,
                                                :pruritus ,
                                                :rash ,
                                                :vomiting ;
          OpenPVSignal:refers_to_patient :Patient18 ;
          OpenPVSignal:refers_to_primary_suspect_drug :golimumab ;
          OpenPVSignal:refers_to_secondary_suspect_drug :ibuprofen ,
                                                        :infliximab ;
          OpenPVSignal:refers_to_outcome_after_action "unknown" ;
          rdfs:label "Report 18" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReport19
:Report19 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:has_free_text_reporting_element :infoForCase19 ;
          OpenPVSignal:refers_to_adverse_effect :arthralgia ,
                                                :arthritisa ,
                                                :back_injury ,
                                                :coma ,
                                                :constipation ,
                                                :fever ,
                                                :fracture ,
                                                :medicalDeviceComplication ,
                                                :medicationError ,
                                                :medicineIneffective ,
                                                :migraine ,
                                                :muscle_strain ,
                                                :pneumothorax ,
                                                :weight_decrease ;
          OpenPVSignal:refers_to_concomitant_drug :acetylsalicylicAcid ,
                                                  :calcitonin ,
                                                  :calcitriol ,
                                                  :clobetasol ,
                                                  :clonazepam ,
                                                  :desonide ,
                                                  :dimenhydrinate ,
                                                  :dorzolamide ,
                                                  :ergocalciferol ,
                                                  :fentanyl ,
                                                  :folicAcid ,
                                                  :lactulose ,
                                                  :methotrexate ,
                                                  :prednisolone ,
                                                  :prednisone ,
                                                  :tacrolimus ,
                                                  :teriparatide ;
          OpenPVSignal:refers_to_patient :Patient19 ;
          OpenPVSignal:refers_to_primary_suspect_drug :golimumab ;
          OpenPVSignal:refers_to_secondary_suspect_drug :hydromorphone ;
          OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
          rdfs:label "Report 19" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReport2
:Report2 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :migraine ;
         OpenPVSignal:refers_to_concomitant_drug :budesonide ,
                                                 :folicAcid ,
                                                 :methotrexate ;
         OpenPVSignal:refers_to_patient :Patient2 ;
         OpenPVSignal:refers_to_primary_suspect_drug :golimumab ;
         OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
         rdfs:label "Report 2" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReport20
:Report20 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :dysgraphia ,
                                                :dyskinesia ,
                                                :fatigue ,
                                                :migraine ,
                                                :speechDisorder ;
          OpenPVSignal:refers_to_concomitant_drug :hydroxychloroquine ,
                                                  :meloxicam ,
                                                  :vitamins ;
          OpenPVSignal:refers_to_patient :Patient20 ;
          OpenPVSignal:refers_to_primary_suspect_drug :golimumab ;
          OpenPVSignal:refers_to_secondary_suspect_drug :adalimumab ,
                                                        :etanercept ,
                                                        :methotrexate ;
          OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
          rdfs:label "Report 20" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReport21
:Report21 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :dysgraphia ,
                                                :dyskinesia ,
                                                :fatigue ,
                                                :migraine ,
                                                :speechDisorder ;
          OpenPVSignal:refers_to_concomitant_drug :hydroxychloroquine ,
                                                  :meloxicam ,
                                                  :vitamins ;
          OpenPVSignal:refers_to_patient :Patient21 ;
          OpenPVSignal:refers_to_primary_suspect_drug :golimumab ;
          OpenPVSignal:refers_to_secondary_suspect_drug :adalimumab ,
                                                        :etanercept ,
                                                        :methotrexate ;
          OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
          rdfs:label "Report 21" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReport22
:Report22 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :constipation ,
                                                :fatigue ,
                                                :headache ,
                                                :migraineAggravated ;
          OpenPVSignal:refers_to_patient :Patient22 ;
          OpenPVSignal:refers_to_primary_suspect_drug :golimumab ;
          OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
          rdfs:label "Report 22" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReport3
:Report3 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :arthralgia ,
                                               :depressionAggravated ,
                                               :heartMurmur ,
                                               :influenza-likeSymptoms ,
                                               :malaise ,
                                               :migraine ,
                                               :oedemaPeripheral ,
                                               :phlebitis ;
         OpenPVSignal:refers_to_patient :Patient3 ;
         OpenPVSignal:refers_to_primary_suspect_drug :golimumab ;
         OpenPVSignal:refers_to_outcome_after_action "unknown" ;
         rdfs:label "Report 3" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReport4
:Report4 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :infectionStaphylococcal ,
                                               :migraine ;
         OpenPVSignal:refers_to_patient :Patient4 ;
         OpenPVSignal:refers_to_primary_suspect_drug :golimumab ;
         OpenPVSignal:refers_to_outcome_after_action "unknown" ;
         rdfs:label "Report 4" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReport5
:Report5 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :headache ,
                                               :migraine ,
                                               :vomiting ;
         OpenPVSignal:refers_to_patient :Patient5 ;
         OpenPVSignal:refers_to_primary_suspect_drug :golimumab ;
         OpenPVSignal:refers_to_outcome_after_action "unknown" ;
         rdfs:label "Report 5" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReport6
:Report6 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :hypertension ,
                                               :medicationError ,
                                               :migraine ,
                                               :therapeuticResponseIncreased ;
         OpenPVSignal:refers_to_concomitant_drug :ascorbicAcid ,
                                                 :ciclosporin ,
                                                 :cyanocobalamin ,
                                                 :dicycloverine ,
                                                 :docusate ,
                                                 :ergocalciferol ,
                                                 :fishOil ,
                                                 :fluticasone ,
                                                 :hydrocodone ,
                                                 :lidocaine ,
                                                 :macrogol ,
                                                 :methadone ,
                                                 :ondansetron ,
                                                 :pantoprazole ,
                                                 :pyridoxine ,
                                                 :salbutamol ,
                                                 :sumatriptan ,
                                                 :topirimate ,
                                                 :vitaminsNos ,
                                                 <http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraine#ergocalciferol/calciumphosphate/calciumSodiumLactate> ;
         OpenPVSignal:refers_to_patient :Patient6 ;
         OpenPVSignal:refers_to_primary_suspect_drug :golimumab ;
         OpenPVSignal:refers_to_outcome_after_action "no recovery" ;
         rdfs:label "Report 6" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReport7
:Report7 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :migraine ,
                                               :rashErythematous ,
                                               :visionAbnormal ;
         OpenPVSignal:refers_to_patient :Patient7 ;
         OpenPVSignal:refers_to_primary_suspect_drug :golimumab ;
         OpenPVSignal:refers_to_outcome_after_action "no recovery" ;
         rdfs:label "Report 7" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReport8
:Report8 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :fatigue ,
                                               :gaitAbnormal ,
                                               :headache ,
                                               :hypoaesthesia ,
                                               :injectionSiteBleeding ,
                                               :madarosis ,
                                               :medicationError ,
                                               :migraine ,
                                               :painInExtremity ,
                                               :paraesthesia ,
                                               :upperRespiratoryTractInfection ;
         OpenPVSignal:refers_to_concomitant_drug :fexofenadine ,
                                                 :fluticasone ,
                                                 :methylprednisolone ,
                                                 :oralContraceptiveNos ,
                                                 :rizatriptan ,
                                                 :topirimate ,
                                                 <http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraine#ethinylestradiol/desogestrel> ;
         OpenPVSignal:refers_to_patient :Patient8 ;
         OpenPVSignal:refers_to_primary_suspect_drug :golimumab ;
         OpenPVSignal:refers_to_secondary_suspect_drug :adalimumab ;
         OpenPVSignal:refers_to_outcome_after_action "no recovery" ;
         rdfs:label "Report 8" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReport9
:Report9 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :hypoaesthesia ,
                                               :hypokinesia ,
                                               :migraine ,
                                               :paraesthesia ;
         OpenPVSignal:refers_to_patient :Patient9 ;
         OpenPVSignal:refers_to_primary_suspect_drug :golimumab ;
         OpenPVSignal:refers_to_outcome_after_action "unknown" ;
         rdfs:label "Report 9" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReportsWithAS
:ReportsWithAS rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Reports_group ;
               OpenPVSignal:concerns_indication_for_use :ankylosingSpondylitis ;
               OpenPVSignal:is_subgroup_of :OverallReportsWithGolimumabAndMigraine ;
               OpenPVSignal:has_count 4 ;
               OpenPVSignal:refers_to_database "WHO Vigibase" ;
               rdfs:label "Reports with AS" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReportsWithDosageInformation
:ReportsWithDosageInformation rdf:type owl:NamedIndividual ,
                                       OpenPVSignal:Reports_group ;
                              OpenPVSignal:is_subgroup_of :OverallReportsWithGolimumabAndMigraine ;
                              OpenPVSignal:refers_to_reported_drug_usage :migraine_usage_for_ReportsWithDosageInformation_1 ;
                              OpenPVSignal:has_count 9 ;
                              OpenPVSignal:refers_to_database "WHO Vigibase" ;
                              rdfs:label "Reports with dosage information" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReportsWithGolimumabAsTheOnlyDrugSuspected
:ReportsWithGolimumabAsTheOnlyDrugSuspected rdf:type owl:NamedIndividual ,
                                                     OpenPVSignal:Reports_group ;
                                            OpenPVSignal:is_subgroup_of :OverallReportsWithGolimumabAndMigraine ;
                                            OpenPVSignal:refers_to_primary_suspect_drug :golimumab ;
                                            OpenPVSignal:has_count 15 ;
                                            OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                            rdfs:label "Reports with golimumab as the only drug suspected" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReportsWithNoRecoveryAsOutcome
:ReportsWithNoRecoveryAsOutcome rdf:type owl:NamedIndividual ,
                                         OpenPVSignal:Reports_group ;
                                OpenPVSignal:is_subgroup_of :OverallReportsWithGolimumabAndMigraine ;
                                OpenPVSignal:has_count 3 ;
                                OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                OpenPVSignal:refers_to_outcome_after_action "no recovery" ;
                                rdfs:label "Reports with no recovery as outcome" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReportsWithNoRecoveryAsOutcomeAndDechallenge
:ReportsWithNoRecoveryAsOutcomeAndDechallenge rdf:type owl:NamedIndividual ,
                                                       OpenPVSignal:Reports_group ;
                                              OpenPVSignal:is_subgroup_of :ReportsWithNoRecoveryAsOutcome ;
                                              OpenPVSignal:has_count 1 ;
                                              OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                              OpenPVSignal:refers_to_dechallenge_outcome "negative - condition still applied" ;
                                              rdfs:label "Reports with no recovery as outcome and dechallenge" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReportsWithPsoriasis
:ReportsWithPsoriasis rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Reports_group ;
                      OpenPVSignal:concerns_indication_for_use :psoriasis ;
                      OpenPVSignal:is_subgroup_of :OverallReportsWithGolimumabAndMigraine ;
                      OpenPVSignal:has_count 1 ;
                      OpenPVSignal:refers_to_database "WHO Vigibase" ;
                      rdfs:label "Reports with psoriasis" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReportsWithRecoveryAsOutcome
:ReportsWithRecoveryAsOutcome rdf:type owl:NamedIndividual ,
                                       OpenPVSignal:Reports_group ;
                              OpenPVSignal:is_subgroup_of :OverallReportsWithGolimumabAndMigraine ;
                              OpenPVSignal:has_count 1 ;
                              OpenPVSignal:refers_to_database "WHO Vigibase" ;
                              OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
                              rdfs:label "Reports with recovery without further info" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReportsWithRecoveryAsOutcomeAndDechallenge
:ReportsWithRecoveryAsOutcomeAndDechallenge rdf:type owl:NamedIndividual ,
                                                     OpenPVSignal:Reports_group ;
                                            OpenPVSignal:is_subgroup_of :OverallReportsWithGolimumabAndMigraine ;
                                            OpenPVSignal:has_count 5 ;
                                            OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                            OpenPVSignal:refers_to_dechallenge_outcome "positive - condition not applied" ;
                                            OpenPVSignal:refers_to_outcome_after_action "recovery after drug withdrawal" ;
                                            rdfs:label "Reports with recovery after drug withdrawl" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReportsWithRheumatoidArthritis
:ReportsWithRheumatoidArthritis rdf:type owl:NamedIndividual ,
                                         OpenPVSignal:Reports_group ;
                                OpenPVSignal:concerns_indication_for_use :rheumatoidArthritis ;
                                OpenPVSignal:is_subgroup_of :OverallReportsWithGolimumabAndMigraine ;
                                OpenPVSignal:has_count 7 ;
                                OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                rdfs:label "Reports with RA" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReportsWithScAdministrationOfGolimumab
:ReportsWithScAdministrationOfGolimumab rdf:type owl:NamedIndividual ,
                                                 OpenPVSignal:Reports_group ;
                                        OpenPVSignal:is_subgroup_of :OverallReportsWithGolimumabAndMigraine ;
                                        OpenPVSignal:has_count 17 ;
                                        OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                        OpenPVSignal:refers_to_form_of_intake "subcutaneous" ;
                                        rdfs:label "Reports with sc administration of golimumab" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReportsWithTimeToOnsetAsInformation
:ReportsWithTimeToOnsetAsInformation rdf:type owl:NamedIndividual ,
                                              OpenPVSignal:Reports_group ;
                                     OpenPVSignal:is_subgroup_of :OverallReportsWithGolimumabAndMigraine ;
                                     OpenPVSignal:time_to_onset :TimeToOnsetForGolimumabAndMigraine ;
                                     OpenPVSignal:has_count 7 ;
                                     OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                     rdfs:label "Reports with time to onset as information" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReports_from_Australia
:Reports_from_Australia rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Reports_group ;
                        OpenPVSignal:is_subgroup_of :OverallReportsWithGolimumabAndMigraine ;
                        OpenPVSignal:has_count 1 ;
                        OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Australia" ;
                        OpenPVSignal:refers_to_database "WHO Vigibase" ;
                        rdfs:label "Reports from Australia" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReports_from_Canada
:Reports_from_Canada rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Reports_group ;
                     OpenPVSignal:is_subgroup_of :OverallReportsWithGolimumabAndMigraine ;
                     OpenPVSignal:has_count 4 ;
                     OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Canada" ;
                     OpenPVSignal:refers_to_database "WHO Vigibase" ;
                     rdfs:label "Reports from Canada" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReports_from_Denmark
:Reports_from_Denmark rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Reports_group ;
                      OpenPVSignal:is_subgroup_of :OverallReportsWithGolimumabAndMigraine ;
                      OpenPVSignal:has_count 1 ;
                      OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Denmark" ;
                      OpenPVSignal:refers_to_database "WHO Vigibase" ;
                      rdfs:label "Reports from Denmark" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReports_from_Sweden
:Reports_from_Sweden rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Reports_group ;
                     OpenPVSignal:is_subgroup_of :OverallReportsWithGolimumabAndMigraine ;
                     OpenPVSignal:has_count 3 ;
                     OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Sweden" ;
                     OpenPVSignal:refers_to_database "WHO Vigibase" ;
                     rdfs:label "Reports from Sweden" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReports_from_Switzerland
:Reports_from_Switzerland rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Reports_group ;
                          OpenPVSignal:is_subgroup_of :OverallReportsWithGolimumabAndMigraine ;
                          OpenPVSignal:has_count 1 ;
                          OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Switzerland" ;
                          OpenPVSignal:refers_to_database "WHO Vigibase" ;
                          rdfs:label "Reports from Switzerland" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReports_from_UK
:Reports_from_UK rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Reports_group ;
                 OpenPVSignal:is_subgroup_of :OverallReportsWithGolimumabAndMigraine ;
                 OpenPVSignal:has_count 1 ;
                 OpenPVSignal:refers_to_country "http://dbpedia.org/resource/United_Kingdom" ;
                 OpenPVSignal:refers_to_database "WHO Vigibase" ;
                 rdfs:label "Reports from UK" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReports_from_US
:Reports_from_US rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Reports_group ;
                 OpenPVSignal:is_subgroup_of :OverallReportsWithGolimumabAndMigraine ;
                 OpenPVSignal:has_count 9 ;
                 OpenPVSignal:refers_to_country "http://dbpedia.org/resource/United_States" ;
                 OpenPVSignal:refers_to_database "WHO Vigibase" ;
                 rdfs:label "Reports from US" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReports_in_Vigibase
:Reports_in_Vigibase rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Free_text_reporting_element ;
                     OpenPVSignal:has_content "As of 1 September 2014 there are 21 ICSRs of migraine and one report of migraine aggravated (WHO-ART preferred terms) in association with golimumab in the WHO Global ICSR database, Vigibase® (Table 1). After the elimination of two duplicates, the reports were submitted from the United States (nine reports), Canada (four reports), Sweden (three reports), and Australia, Denmark, Switzerland and the United Kingdom (one report each). The patients ranged in age from 37 to 77 years with a median of 59 years in the 11 cases which provided the information. There were 18 females and two males. Golimumab was the only drug suspected in 15 of the 20 cases. There were other drugs also suspected in the remaining five cases and they were mostly drugs probably being used for the same indication as golimumab. These drugs included adalimumab and hydromorphone in one report each, both infliximab and ibuprofen in one report and adalimumab, etanercept and MTX in another report. In the remaining report, pandemic influenza vaccine was suspected. Concomitant drugs were reported in nine of the 20 cases and apart from asthma treatment in three cases, the concomitant drugs were mostly those which might be expected in a patient population with systemic inflammatory disease and included MTX (five cases), folic acid (four), other immunomodifiers or similar drugs (four), NSAIDs (four) and corticosteroids (three). Drugs used for the treatment of migraine were reported in two cases and in another case the reaction term was migraine aggravated. Golimumab was reported to have been administered subcutaneously, as expected, in all 17 cases which provided this information. The indication for use was stated in 14 reports and included RA in seven reports, AS in four reports, and psoriasis, RA/PsA and RA/osteoarthritis in one report each. In all nine cases which provided information on both dose and dosage regimen, the drug was administered monthly at 50 mg. Time to onset was reported in five of the reports and ranged from the same day the drug was administered to eight months (median four weeks). Two other reports appeared to indicate that onset was within a month. The outcome of the migraine was stated in nine reports. Six of these patients were reported as recovered and the remaining three patients had not recovered. In the six cases with recovery, golimumab was withdrawn in five cases and the fate of the drug was unclear in the other case. In the three cases where the patients had not recovered at the time of reporting, the drug was withdrawn in one case, it was reported to only have been given once in one case and continued in the other case. Other reactions were reported in all but two cases. These included a wide variety of reactions but the most common were those which may be expected to accompany migraine such as headache (five reports), vision abnormal (three), hypoaesthesia (three), paraesthesia (three), fatigue (three), and vomiting (two)." ;
                     rdfs:label "Reports in Vigibase" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReports_with_age_info
:Reports_with_age_info rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Reports_group ;
                       OpenPVSignal:is_subgroup_of :OverallReportsWithGolimumabAndMigraine ;
                       OpenPVSignal:has_count 11 ;
                       OpenPVSignal:has_max_age 77 ;
                       OpenPVSignal:has_median_age 59 ;
                       OpenPVSignal:has_min_age 37 ;
                       OpenPVSignal:refers_to_database "WHO Vigibase" ;
                       rdfs:label "Reports with age info" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReports_with_fatigue
:Reports_with_fatigue rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Reports_group ;
                      OpenPVSignal:is_subgroup_of :OverallReportsWithGolimumabAndMigraine ;
                      OpenPVSignal:refers_to_adverse_effect :fatigue ;
                      OpenPVSignal:has_count 3 ;
                      OpenPVSignal:refers_to_database "WHO Vigibase" ;
                      rdfs:label "Reports with fatigue" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReports_with_headache
:Reports_with_headache rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Reports_group ;
                       OpenPVSignal:is_subgroup_of :OverallReportsWithGolimumabAndMigraine ;
                       OpenPVSignal:refers_to_adverse_effect :headache ;
                       OpenPVSignal:has_count 5 ;
                       OpenPVSignal:refers_to_database "WHO Vigibase" ;
                       rdfs:label "Reports with headache" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReports_with_hypoaesthesia
:Reports_with_hypoaesthesia rdf:type owl:NamedIndividual ,
                                     OpenPVSignal:Reports_group ;
                            OpenPVSignal:is_subgroup_of :OverallReportsWithGolimumabAndMigraine ;
                            OpenPVSignal:refers_to_adverse_effect :hypoaesthesia ;
                            OpenPVSignal:has_count 3 ;
                            OpenPVSignal:refers_to_database "WHO Vigibase" ;
                            rdfs:label "Reports with hypoaesthesia" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReports_with_paraestesia
:Reports_with_paraestesia rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Reports_group ;
                          OpenPVSignal:is_subgroup_of :OverallReportsWithGolimumabAndMigraine ;
                          OpenPVSignal:refers_to_adverse_effect :paraesthesia ;
                          OpenPVSignal:has_count 3 ;
                          OpenPVSignal:refers_to_database "WHO Vigibase" ;
                          rdfs:label "Reports with paraestesia" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReports_with_vision_abnormal
:Reports_with_vision_abnormal rdf:type owl:NamedIndividual ,
                                       OpenPVSignal:Reports_group ;
                              OpenPVSignal:is_subgroup_of :OverallReportsWithGolimumabAndMigraine ;
                              OpenPVSignal:refers_to_adverse_effect :visionAbnormal ;
                              OpenPVSignal:has_count 3 ;
                              OpenPVSignal:refers_to_database "WHO Vigibase" ;
                              rdfs:label "Reports with vision abnormal" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineReports_with_vomiting
:Reports_with_vomiting rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Reports_group ;
                       OpenPVSignal:is_subgroup_of :OverallReportsWithGolimumabAndMigraine ;
                       OpenPVSignal:refers_to_adverse_effect :vomiting ;
                       OpenPVSignal:has_count 2 ;
                       OpenPVSignal:refers_to_database "WHO Vigibase" ;
                       rdfs:label "Reports with vomiting" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineResponse_from_Janssen
:Response_from_Janssen rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Response_to_Pharmacovigilance_Signal_Report ;
                       OpenPVSignal:refers_to_pharmacovigilance_signal_report :Golimumab_and_Migraine ;
                       OpenPVSignal:has_content """Response from Janssen
Golimumab is one of several TNF-blocking agents that are available for the treatment of diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and ulcerative colitis (UC). Janssen actively evaluates available safety data from multiple sources to identify new safety signals and works closely with health authorities to accurately inform patients and prescribers about the safety profile of golimumab.
In response to this signal notification, Janssen performed a review of literature, the clinical trial database, and cumulative reports of migraine with golimumab therapy that were contained in the Janssen worldwide safety database. Janssen also conducted searches of the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database/ WHO Global ICSR Database System (Vigibase®) and the Janssen worldwide safety database for reports involving the use of golimumab and coded to a set of MedDRA Preferred terms (PTs) representative of migraine for a signal of disproportionality. The search used the most currently available, cumulative data from the FAERS database through March 31, 2014, and the WHO Vigibase®, through September 30 2014, and the Janssen worldwide safety database cumulatively though 26 November 2014. The results of the analysis are provided below. A literature search was carried out using PubMed to identify any reports in the literature associating migraine with the use of any TNF-α inhibitors and specifically with the use of golimumab. No reports in the literature were identified associating migraine with the use of golimumab or other TNF- α inhibitors.
Clinical trial data was retrieved from 5 phase 3 subcutaneous studies (3 RA, 1 PsA, 1 AS), 2 phase 3 intravenous RA studies, and 2 phase 2/3 UC studies for the pure placebo-controlled period in which 1,372 subjects were exposed to placebo and 3,513 subjects were exposed to golimumab.
Subjects in both golimumab-treated and placebo- treated arms reported the PT of Migraine at a frequency of 0.4%. The frequency of the PT Migraine with aura reported as 0.1% in the placebo arm and 0.0% in the golimumab arm.
The Janssen worldwide safety database was searched for the following PTs: Migraine, Basilar migraine, Retinal migraine, Migraine with aura, Abdominal migraine, Hemiplegic migraine, Ophthalmoplegic migraine, Migraine without aura, Familial hemiplegic migraine, Stroke-like migraine attacks after radiation therapy, Migrainous infarction, or Status migrainosus. The search retrieved 98 reports for the PT of Migraine and 1 report for the PT of Migraine with aura. No disproportionality alerts were observed for either PT in the database. WHO Global Individual Case Safety report database, Vigibase® data mining of Migraine as of the September 30, 2014 included 22 reports associated with golimumab. No disproportionality was observed for the retrieved dataset. FAERS data mining of Migraine as of the March 31, 2014 included 21 reports associated with golimumab. No disproportionality was observed for the retrieved dataset.
A review of the 99 reports retrieved from the Janssen worldwide safety database elucidated the following details. One report was a duplicate report; 7 reports provided adequate detail without confounding factors; 24 reports involved patients with medical history of headaches/migraines; 10 reports involved patients with co-morbid conditions associated with migraines; and 57 reports provided limited information, including medical history, co suspect/concomitant medications, indication, latency, clinical course of events, treatment, or outcome, precluding an adequate medical assessment. Individual and aggregate review of those reports providing adequate information did not indicate an association between migraine and golimumab use, either for new onset or worsening of existing conditions of migraine.
Based on this review of data from the Janssen worldwide safety database, the clinical trial database, the literature, the WHO Vigibase®, and FAERS database, migraine is not considered associated with the use of golimumab. Key factors supporting this conclusion include the extensive data from the clinical trials showing a balance between subjects receiving placebo or golimumab, the lack of disproportionality in the various databases, the lack of literature supporting the association, the low reporting rate coupled with the common frequency of migraine in the population as noted by WHO, and the review of individual reports of migraine found in the Janssen worldwide safety database. No changes to the golimumab labelling/prescribing information are warranted at this time, and the benefit-risk ratio for patients treated with golimumab for RA, PsA, AS or UC remains favourable.""" ;
                       rdfs:label "Response from Janssen" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineSummaryContent
:SummaryContent rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Summary ;
                OpenPVSignal:has_content """Golimumab is a human monoclonal antibody that forms high affinity, stable complexes with both the soluble and transmembrane bioactive forms of human tumour necrosis factor (TNF)-α, which prevents the binding of TNF-α to its receptors. It is indicated for the treatment of ulcerative colitis (UC), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and rheumatoid arthritis (RA) in combination with methotrexate (MTX). After the elimination of duplicates there are currently (1 September 2014) 20 ICSRs in the WHO Global ICSR database, Vigibase® of migraine in association with golimumab. The reports are from Australia, Canada, Denmark, Sweden, Switzerland, the United Kingdom and the United States.
Golimumab was the only drug suspected in 15 of
the 20 cases. The outcome of the migraine was stated in nine reports. Six of these patients were reported as recovered and the remaining three patients had not recovered. In the six cases with recovery, golimumab was withdrawn in five cases and the fate of the drug was unclear in the other case. In the three cases where the patients had not recovered, the drug was withdrawn in two cases and continued in the other case.
Case reports in Vigibase® suggest that there is a possible signal for the association of golimumab and migraine. Although there are alternative explanations such as the use of adalimumab in two reports and the episodic recurrence of migraine in three other reports, the use of golimumab resulting in migraine appears to be a signal. Time to onset is consistent with a drug- induced effect. Migraine is mentioned in the product information of two other TNF-α inhibitors and for one of these drugs as well as an additional TNF-α inhibitor, there are significant reports of the association in Vigibase®. Finally, TNF-α is known to be involved in migraine so a mechanism for the involvement of TNF-α inhibitors in the development of migraine is a possibility.""" ;
                rdfs:label "Summary content" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineTNF-aInhibitorsAndMigraine
:TNF-aInhibitorsAndMigraine rdf:type owl:NamedIndividual ,
                                     obo:OAE_0001197 ;
                            mp:references :Ref.3 ,
                                          :Ref.4 ;
                            OpenPVSignal:has_content "There are also no reports in the literature which link other TNF-α inhibitors with migraine but this reaction is listed as common in the product literature for adalimumab.3 In addition, the product information for another TNF- α inhibitor, certolizumab, indicates that headache, including migraine, is a common reaction.4" ;
                            rdfs:label "TNF-a inhibitors and migraine" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineTNF-a_inhibitors
:TNF-a_inhibitors rdf:type owl:NamedIndividual ,
                           OpenPVSignal:DrugClass ;
                  OpenPVSignal:has_mechanism :PotentialMechanismOfInductionOfMigraineByGolimumab ;
                  OpenPVSignal:has_ATC_code "L04AB" ;
                  rdfs:label "TNF-a inhibitors" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineTimeToOnsetForGolimumabAndMigraine
:TimeToOnsetForGolimumabAndMigraine rdf:type owl:NamedIndividual ,
                                             <http://www.w3.org/2006/time#DurationDescription> ;
                                    OpenPVSignal:has_content "Time to onset was reported in five of the reports and ranged from the same day the drug was administered to eight months (median four weeks). Two other reports appeared to indicate that onset was within a month." ;
                                    rdfs:label "Time to onset for golimumab and migraine" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineUsage_of_Golimumab
:Usage_of_Golimumab rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Drug_Usage ;
                    OpenPVSignal:concerns_indication_for_use :ankylosingSpondylitis ,
                                                             :psoriaticArthritis ,
                                                             :rheumatoidArthritis ,
                                                             :ulcerativeColitis ;
                    OpenPVSignal:refers_to_drug :golimumab ;
                    rdfs:label "Usage of Golimumab" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineabdominalPain
:abdominalPain rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Adverse_Effect ;
               OpenPVSignal:has_MedDRA_code 10000081 ;
               OpenPVSignal:has_MedDRA_prefered_term "Abdominal pain" ;
               rdfs:label "abdominal pain" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineabscess
:abscess rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Adverse_Effect ;
         OpenPVSignal:has_MedDRA_code 10000269 ;
         OpenPVSignal:has_MedDRA_prefered_term "Abscess" ;
         rdfs:label "abscess" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineacetylsalicylicAcid
:acetylsalicylicAcid rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Drug ;
                     OpenPVSignal:has_ATC_code "A01AD05" ,
                                               "B01AC06" ,
                                               "B01AC56" ,
                                               "C10BX01" ,
                                               "C10BX02" ,
                                               "C10BX04" ,
                                               "C10BX05" ,
                                               "C10BX06" ,
                                               "C10BX08" ,
                                               "M01BA03" ,
                                               "N02BA01" ,
                                               "N02BA51" ,
                                               "N02BA71" ;
                     rdfs:label "acetylsalicylic acid" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineadalimumab
:adalimumab rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:hasClass :TNF-a_inhibitors ;
            OpenPVSignal:has_ATC_code "L04AB04" ;
            rdfs:label "adalimumab" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineallergicReaction
:allergicReaction rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Adverse_Effect ;
                  OpenPVSignal:has_MedDRA_code 10001718 ;
                  OpenPVSignal:has_MedDRA_prefered_term "Allergic reaction" ;
                  rdfs:label "allergic reaction" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineanaemia
:anaemia rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Adverse_Effect ;
         OpenPVSignal:has_MedDRA_code 10002034 ;
         OpenPVSignal:has_MedDRA_prefered_term "Anaemia" ;
         rdfs:label "anaemia" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineankylosingSpondylitis
:ankylosingSpondylitis rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Indication ;
                       OpenPVSignal:has_ICD_code "M45" ;
                       OpenPVSignal:has_MedDRA_code 10002556 ;
                       OpenPVSignal:has_MedDRA_prefered_term "Ankylosing spondylitis" ;
                       rdfs:label "ankylosing spondylitis" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineantihypertensives
:antihypertensives rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Drug ;
                   OpenPVSignal:has_ATC_code "C02" ;
                   rdfs:label "antihypertensives" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineanxiety
:anxiety rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Adverse_Effect ;
         OpenPVSignal:has_MedDRA_code 10002855 ;
         OpenPVSignal:has_MedDRA_prefered_term "Anxiety" ;
         rdfs:label "anxiety" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainearthralgia
:arthralgia rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Adverse_Effect ;
            OpenPVSignal:has_MedDRA_code 10003239 ;
            OpenPVSignal:has_MedDRA_prefered_term "Arthralgia" ;
            rdfs:label "arthralgia" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainearthritisa
:arthritisa rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Adverse_Effect ;
            OpenPVSignal:has_MedDRA_code 10003246 ;
            OpenPVSignal:has_MedDRA_prefered_term "Arthritis" ;
            rdfs:label "arthritis" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineascorbicAcid
:ascorbicAcid rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "A11GA01" ;
              rdfs:label "ascorbic acid" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineasthenia
:asthenia rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_MedDRA_code 10003549 ;
          OpenPVSignal:has_MedDRA_prefered_term "Asthenia" ;
          rdfs:label "asthenia" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineasthma
:asthma rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Adverse_Effect ;
        OpenPVSignal:has_MedDRA_code 10003553 ;
        OpenPVSignal:has_MedDRA_prefered_term "Asthma" ;
        rdfs:label "asthma" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineautoantibodyPositive
:autoantibodyPositive rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Adverse_Effect ;
                      OpenPVSignal:has_MedDRA_code 10060973 ;
                      OpenPVSignal:has_MedDRA_prefered_term "Autoantibody positive" ;
                      rdfs:label "autoantibody positive" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineback_injury
:back_injury rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_MedDRA_code 10003986 ;
             OpenPVSignal:has_MedDRA_prefered_term "Back injury" ;
             rdfs:label "back injury" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainebacterialInfections
:bacterialInfections rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_MedDRA_code 10060945 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Bacterial infection" ;
                     rdfs:label "bacterial infections" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainebetamethasone
:betamethasone rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Drug ;
               OpenPVSignal:has_ATC_code "A07EA04" ,
                                         "C05AA05" ,
                                         "D07AC01" ,
                                         "D07BC01" ,
                                         "D07CC01" ,
                                         "D07XC01" ,
                                         "H02AB01" ,
                                         "R01AD06" ,
                                         "R03BA04" ,
                                         "S01BA06" ,
                                         "S01BB04" ,
                                         "S01CA05" ,
                                         "S01CB04" ,
                                         "S02BA07" ,
                                         "S03BA03" ,
                                         "S03CA06" ;
               rdfs:label "betamethasone" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainebronchitis
:bronchitis rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Adverse_Effect ;
            OpenPVSignal:has_MedDRA_code 10006451 ;
            OpenPVSignal:has_MedDRA_prefered_term "Bronchitis" ;
            rdfs:label "bronchitis" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainebudesonide
:budesonide rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "R03BA02" ;
            rdfs:label "budesonide" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainecalcitonin
:calcitonin rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "H05BA" ;
            rdfs:label "calcitonin" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainecalcitriol
:calcitriol rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "A11CC04" ,
                                      "D05AX03" ;
            rdfs:label "calcitriol" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainecertolizumab
:certolizumab rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:hasClass :TNF-a_inhibitors ;
              OpenPVSignal:has_ATC_code "L04AB05" ;
              rdfs:label "certolizumab" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineciclosporin
:ciclosporin rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "L04AD01 " ;
             rdfs:label "ciclosporin" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineclobetasol
:clobetasol rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "D07AD01" ,
                                      "D07CD01" ;
            rdfs:label "clobetasol" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineclonazepam
:clonazepam rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "N03AE01" ;
            rdfs:label "clonazepam" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainecoma
:coma rdf:type owl:NamedIndividual ,
               OpenPVSignal:Adverse_Effect ;
      OpenPVSignal:has_ICD_code "R40.20" ;
      OpenPVSignal:has_MedDRA_code 10010071 ;
      OpenPVSignal:has_MedDRA_prefered_term "Coma" ;
      rdfs:label "coma" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainecongestiveHeartFailure
:congestiveHeartFailure rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Adverse_Effect ;
                        OpenPVSignal:has_MedDRA_code 10010684 ;
                        OpenPVSignal:has_MedDRA_prefered_term "Congestive heart failure" ;
                        rdfs:label "congestive heart failure" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineconstipation
:constipation rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_ICD_code "K59.00" ;
              OpenPVSignal:has_MedDRA_code 10010774 ;
              OpenPVSignal:has_MedDRA_prefered_term "Constipation" ;
              rdfs:label "Constipation" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainecoughing
:coughing rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_MedDRA_code 10011232 ;
          OpenPVSignal:has_MedDRA_prefered_term "Coughing" ;
          rdfs:label "coughing" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainecyanocobalamin
:cyanocobalamin rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Drug ;
                OpenPVSignal:has_ATC_code "B03AE01" ,
                                          "B03BA01" ,
                                          "B03BA51" ;
                rdfs:label "cyanocobalamin" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrained
:d rdf:type owl:NamedIndividual ,
            OpenPVSignal:Warning_Information ;
   OpenPVSignal:refers_to_adverse_effect :abscess ,
                                         :allergicReaction ,
                                         :anaemia ,
                                         :asthenia ,
                                         :asthma ,
                                         :autoantibodyPositive ,
                                         :bacterialInfections ,
                                         :bronchitis ,
                                         :depression ,
                                         :dizziness ,
                                         :gastrointestinalDisorders ,
                                         :headache ,
                                         :hypertension ,
                                         :increasesInLiverFunctionTests ,
                                         :injectionSiteReaction ,
                                         :insomnia ,
                                         :lowerRespiratoryTractInfection ,
                                         :paraesthesia ,
                                         :pyrexia ,
                                         :sinusitis ,
                                         :skinDisorders ,
                                         :subcutaneousTissueDisorders ,
                                         :superficialFungalInfections ,
                                         :upperRespiratoryTractInfection ,
                                         :viralInfections ;
   OpenPVSignal:refers_to_drug :golimumab ;
   mp:references :Ref.1 ;
   OpenPVSignal:has_content "The adverse reactions which have been reported commonly or very commonly include infections and infestations such as upper respiratory tract infection, bacterial infections, lower respiratory tract infection, viral infections, bronchitis, sinusitis, superficial fungal infections, and abscess; immune system disorders such as allergic reactions and autoantibody positive; nervous system disorders such as dizziness, headache and paraesthesia; gastrointestinal disorders; skin and subcutaneous tissue disorders; general disorders and administration site conditions such as pyrexia, asthenia, and injection site reaction; depression, insomnia, increases in liver function tests, asthma, hypertension and anaemia.1" ;
   rdfs:label "common ADRs" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainedecongestants
:decongestants rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Drug ;
               OpenPVSignal:has_ATC_code "R01A" ;
               rdfs:label "decongestants" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainedemyelinatingDisorders
:demyelinatingDisorders rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Adverse_Effect ;
                        OpenPVSignal:has_MedDRA_code 10012303 ;
                        OpenPVSignal:has_MedDRA_prefered_term "Demyelinating disorders" ;
                        rdfs:label "demyelinating disorders" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainedepression
:depression rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Adverse_Effect ;
            OpenPVSignal:has_ICD_code "F33" ;
            OpenPVSignal:has_MedDRA_code 10012378 ;
            OpenPVSignal:has_MedDRA_prefered_term "Depression" ;
            rdfs:label "depression" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainedepressionAggravated
:depressionAggravated rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Adverse_Effect ;
                      OpenPVSignal:has_MedDRA_code 10012379 ;
                      OpenPVSignal:has_MedDRA_prefered_term "Depression aggravated" ;
                      rdfs:label "depression aggravated" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainedesonide
:desonide rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Drug ;
          OpenPVSignal:has_ATC_code "D07AB08" ,
                                    "D07BB02" ,
                                    "S01BA11" ;
          rdfs:label "desonide" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainedicycloverine
:dicycloverine rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Drug ;
               OpenPVSignal:has_ATC_code "A03AA07 " ;
               rdfs:label "dicycloverine" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainedimenhydrinate
:dimenhydrinate rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Drug ;
                OpenPVSignal:has_ATC_code "R06AA52" ;
                rdfs:label "dimenhydrinate" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainedisorders
:disorders rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_MedDRA_code 10049848 ;
           OpenPVSignal:has_MedDRA_prefered_term "Balance disorder" ;
           rdfs:label "balance disorders" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainedizziness
:dizziness rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_MedDRA_code 10013573 ;
           OpenPVSignal:has_MedDRA_prefered_term "Dizziness" ;
           rdfs:label "dizziness" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainedocusate
:docusate rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Drug ;
          OpenPVSignal:has_ATC_code "A06AA02" ,
                                    "A06AG10" ;
          rdfs:label "docusate" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainedorzolamide
:dorzolamide rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "S01EC03" ;
             rdfs:label "dorzolamide" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainedysgeusia
:dysgeusia rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_ICD_code "J93.9" ;
           OpenPVSignal:has_MedDRA_code 10013911 ;
           OpenPVSignal:has_MedDRA_prefered_term "Dysgeusia" ;
           rdfs:label "Dysgeusia" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainedysgraphia
:dysgraphia rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Adverse_Effect ;
            OpenPVSignal:has_ICD_code "R278" ;
            OpenPVSignal:has_MedDRA_code 10058319 ;
            OpenPVSignal:has_MedDRA_prefered_term "Dysgraphia" ;
            rdfs:label "Dysgraphia" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainedyskinesia
:dyskinesia rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Adverse_Effect ;
            OpenPVSignal:has_ICD_code "G24.01" ;
            OpenPVSignal:has_MedDRA_code 10013916 ;
            OpenPVSignal:has_MedDRA_prefered_term "Dyskinesia" ;
            rdfs:label "Dyskinesia" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainedysphemia
:dysphemia rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_MedDRA_code 10054964 ;
           OpenPVSignal:has_MedDRA_prefered_term "Dysphemia" ;
           rdfs:label "dysphemia" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineergocalciferol
:ergocalciferol rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Drug ;
                OpenPVSignal:has_ATC_code "A11CC01" ;
                rdfs:label "ergocalciferol" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineetanercept
:etanercept rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "L04AB01" ;
            rdfs:label "etanercept" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineeyePain
:eyePain rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Adverse_Effect ;
         OpenPVSignal:has_MedDRA_code 10015958 ;
         OpenPVSignal:has_MedDRA_prefered_term "Eye pain" ;
         rdfs:label "eye pain" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainefatigue
:fatigue rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Adverse_Effect ;
         OpenPVSignal:has_MedDRA_code 10016256 ;
         OpenPVSignal:has_MedDRA_prefered_term "Fatigue" ;
         rdfs:label "fatigue" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainefentanyl
:fentanyl rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Drug ;
          OpenPVSignal:has_ATC_code "N01AH01" ,
                                    "N01AH51" ,
                                    "N02AB03" ;
          rdfs:label "fentanyl" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainefever
:fever rdf:type owl:NamedIndividual ,
                OpenPVSignal:Adverse_Effect ;
       OpenPVSignal:has_ICD_code "R50.9" ;
       OpenPVSignal:has_MedDRA_code 10037660 ;
       OpenPVSignal:has_MedDRA_prefered_term "Pyrexia" ;
       rdfs:label "fever" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainefexofenadine
:fexofenadine rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "R06AX26" ;
              rdfs:label "fexofenadine" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainefishOil
:fishOil rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Drug ;
         rdfs:label "fish oil" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainefluticasone
:fluticasone rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "D07AC17" ,
                                       "R01AD08" ,
                                       "R01AD58" ,
                                       "R03AK06" ,
                                       "R03AK11" ,
                                       "R03BA05" ;
             rdfs:label "fluticasone" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainefolicAcid
:folicAcid rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "B03AE01" ,
                                     "B03AE02" ,
                                     "B03BB01" ,
                                     "B03BB51" ;
           rdfs:label "folic acid" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainefracture
:fracture rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_MedDRA_code 10017076 ;
          OpenPVSignal:has_MedDRA_prefered_term "Fracture" ;
          rdfs:label "fracture" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainegaitAbnormal
:gaitAbnormal rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_MedDRA_code 10017573 ;
              OpenPVSignal:has_MedDRA_prefered_term "Gait abnormal" ;
              rdfs:label "gait abnormal" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainegastrointestinalDisorders
:gastrointestinalDisorders rdf:type owl:NamedIndividual ,
                                    OpenPVSignal:Adverse_Effect ;
                           OpenPVSignal:has_MedDRA_code 10017947 ;
                           OpenPVSignal:has_MedDRA_prefered_term "Gastrointestinal disorders" ;
                           rdfs:label "gastrointestinal disorders" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainegiHaemorrhage
:giHaemorrhage rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Adverse_Effect ;
               OpenPVSignal:has_MedDRA_code 10017955 ;
               OpenPVSignal:has_MedDRA_prefered_term "Gastrointestinal haemorrhage" ;
               rdfs:label "gi haemorrhage" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainegolimumab
:golimumab rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:hasClass :TNF-a_inhibitors ;
           OpenPVSignal:has_mechanism :Mechanism_of_Golimumab ;
           OpenPVSignal:has_ATC_code "L04AB06" ;
           rdfs:label "golimumab" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainehaematologicalReactions
:haematologicalReactions rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Adverse_Effect ;
                         OpenPVSignal:has_MedDRA_code 10018847 ;
                         OpenPVSignal:has_MedDRA_prefered_term "Haematological disorders" ;
                         rdfs:label "haematological reactions" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainehaemorrhageNos
:haemorrhageNos rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Adverse_Effect ;
                OpenPVSignal:has_MedDRA_code 10018988 ;
                OpenPVSignal:has_MedDRA_prefered_term "Haemorrhage NOS" ;
                rdfs:label "haemorrhage nos" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineheadache
:headache rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_MedDRA_code 10019211 ;
          OpenPVSignal:has_MedDRA_prefered_term "Headache" ;
          rdfs:label "headache" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainehearingDecreased
:hearingDecreased rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Adverse_Effect ;
                  OpenPVSignal:has_MedDRA_code 10019241 ;
                  OpenPVSignal:has_MedDRA_prefered_term "Hearing decreased" ;
                  rdfs:label "hearing decreased" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineheartMurmur
:heartMurmur rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_MedDRA_code 10019295 ;
             OpenPVSignal:has_MedDRA_prefered_term "Heart murmur" ;
             rdfs:label "heart murmur" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainehepatitisBVirusReactivation
:hepatitisBVirusReactivation rdf:type owl:NamedIndividual ,
                                      OpenPVSignal:Adverse_Effect ;
                             OpenPVSignal:has_MedDRA_code 10058827 ;
                             OpenPVSignal:has_MedDRA_prefered_term "Hepatitis B reactivation" ;
                             rdfs:label "hepatitis b virus reactivation" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainehydrochlorothiazide
:hydrochlorothiazide rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Drug ;
                     OpenPVSignal:has_ATC_code "C03AA03" ,
                                               "C03AB03" ,
                                               "C03AX01" ,
                                               "C03EA01" ,
                                               "C09DX01" ,
                                               "C09DX03" ,
                                               "C09XA52" ,
                                               "C09XA54" ,
                                               "G01AE10" ;
                     rdfs:label "hydrochlorothiazide" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainehydrocodone
:hydrocodone rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "R05DA03" ;
             rdfs:label "hydrocodone" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainehydromorphone
:hydromorphone rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Drug ;
               OpenPVSignal:has_ATC_code "N02AA03" ,
                                         "N02AG04" ;
               rdfs:label "hydromorphone" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainehydroxychloroquine
:hydroxychloroquine rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Drug ;
                    OpenPVSignal:has_ATC_code "P01BA02" ;
                    rdfs:label "hydroxychloroquine" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainehypertension
:hypertension rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_MedDRA_code 10020772 ;
              OpenPVSignal:has_MedDRA_prefered_term "Hypertension" ;
              rdfs:label "hypertension" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainehypoaesthesia
:hypoaesthesia rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Adverse_Effect ;
               OpenPVSignal:has_MedDRA_code 10020937 ;
               OpenPVSignal:has_MedDRA_prefered_term "Hypoaesthesia" ;
               rdfs:label "hypoaesthesia" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainehypokinesia
:hypokinesia rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_MedDRA_code 10021021 ;
             OpenPVSignal:has_MedDRA_prefered_term "Hypokinesia" ;
             rdfs:label "hypokinesia" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineibuprofen
:ibuprofen rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "C01EB16" ,
                                     "G02CC01" ,
                                     "M01AE01" ,
                                     "M01AE51" ,
                                     "M02AA13" ,
                                     "R02AX02" ;
           rdfs:label "ibuprofen" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineincidence_in_men
:incidence_in_men rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Incidence ;
                  OpenPVSignal:refers_to_adverse_effect :migraine ;
                  OpenPVSignal:has_content "6% of men over a one year period" ;
                  OpenPVSignal:has_value 0.06 ;
                  rdfs:label "incidence in men" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineincidence_in_women
:incidence_in_women rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Incidence ;
                    OpenPVSignal:refers_to_adverse_effect :migraine ;
                    OpenPVSignal:has_content "15% of women over a one year period" ;
                    OpenPVSignal:has_value 0.15 ;
                    rdfs:label "incidence in women" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineincreasesInLiverFunctionTests
:increasesInLiverFunctionTests rdf:type owl:NamedIndividual ,
                                        OpenPVSignal:Adverse_Effect ;
                               OpenPVSignal:has_MedDRA_code 10077692 ;
                               OpenPVSignal:has_MedDRA_prefered_term "Liver function test increased" ;
                               rdfs:label "increases in liver function tests" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineinfectionStaphylococcal
:infectionStaphylococcal rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Adverse_Effect ;
                         OpenPVSignal:has_MedDRA_code 10048590 ;
                         OpenPVSignal:has_MedDRA_prefered_term "Infection staphylococcal" ;
                         rdfs:label "infection staphylococcal" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineinfliximab
:infliximab rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "L04AB02" ;
            rdfs:label "infliximab" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineinfluenza-likeSymptoms
:influenza-likeSymptoms rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Adverse_Effect ;
                        OpenPVSignal:has_MedDRA_code 10022009 ;
                        OpenPVSignal:has_MedDRA_prefered_term "Influenza-like symptoms" ;
                        rdfs:label "influenza-like symptoms" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineinfluenzaImmunisation
:influenzaImmunisation rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Adverse_Effect ;
                       OpenPVSignal:has_MedDRA_code 10059429 ;
                       OpenPVSignal:has_MedDRA_prefered_term "Influenza immunisation" ;
                       rdfs:label "influenza immunisation" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineinfoForCase1
:infoForCase1 rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Case_Report_Information ;
              OpenPVSignal:has_content "None of the other suspected drugs appear to be a more likely cause than golimumab and in Case 1, the temporal association appears better with golimumab than pandemic influenza vaccine." ;
              rdfs:label "info for case 1" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineinfoForCase19
:infoForCase19 rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Case_Report_Information ;
               OpenPVSignal:has_content "In Case 19, however, the patient recovered after hydromorphone was withdrawn while golimumab was probably continued. This suggests that hydromorphone is a more likely cause. " ;
               rdfs:label "info for case 19" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineinjectionSiteBleeding
:injectionSiteBleeding rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Adverse_Effect ;
                       OpenPVSignal:has_MedDRA_code 10022049 ;
                       OpenPVSignal:has_MedDRA_prefered_term "Injection site bleeding" ;
                       rdfs:label "injection site bleeding" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineinjectionSiteReaction
:injectionSiteReaction rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Adverse_Effect ;
                       OpenPVSignal:has_MedDRA_code 10022095 ;
                       OpenPVSignal:has_MedDRA_prefered_term "Injection site reaction" ;
                       rdfs:label "injection site reaction" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineinsomnia
:insomnia rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_MedDRA_code 10022437 ;
          OpenPVSignal:has_MedDRA_prefered_term "Insomnia" ;
          rdfs:label "insomnia" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineinvasiveFungal
:invasiveFungal rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Adverse_Effect ;
                OpenPVSignal:has_MedDRA_code 10049080 ;
                OpenPVSignal:has_MedDRA_prefered_term "Yeast infection" ;
                rdfs:label "invasive fungal" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainejointFluidDrainage
:jointFluidDrainage rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Adverse_Effect ;
                    OpenPVSignal:has_MedDRA_code 10066994 ;
                    OpenPVSignal:has_MedDRA_prefered_term "Joint fluid drainage" ;
                    rdfs:label "joint fluid drainage" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainelactulose
:lactulose rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "A06AD11" ,
                                     "A06AD61" ;
           rdfs:label "lactulose" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainelevothyroxine
:levothyroxine rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Drug ;
               OpenPVSignal:has_ATC_code "H03AA01" ;
               rdfs:label "levothyroxine" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainelidocaine
:lidocaine rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "C01BB01" ,
                                     "C05AD01" ,
                                     "D04AB01" ,
                                     "N01BB02" ,
                                     "N01BB52" ,
                                     "R02AD02" ,
                                     "S01HA07" ,
                                     "S02DA01" ;
           rdfs:label "lidocaine" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainelowerRespiratoryTractInfection
:lowerRespiratoryTractInfection rdf:type owl:NamedIndividual ,
                                         OpenPVSignal:Adverse_Effect ;
                                OpenPVSignal:has_MedDRA_code 10024968 ;
                                OpenPVSignal:has_MedDRA_prefered_term "Lower respiratory tract infection" ;
                                rdfs:label "lower respiratory tract infection" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainelupus-likeSyndrome
:lupus-likeSyndrome rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Adverse_Effect ;
                    OpenPVSignal:has_MedDRA_code 10050551 ;
                    OpenPVSignal:has_MedDRA_prefered_term "Lupus-like syndrome" ;
                    rdfs:label "lupus-like syndrome" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainelymphoma
:lymphoma rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_MedDRA_code 10025310 ;
          OpenPVSignal:has_MedDRA_prefered_term "Lymphoma" ;
          rdfs:label "lymphoma" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainemacrogol
:macrogol rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Drug ;
          OpenPVSignal:has_ATC_code "A06AD15" ;
          rdfs:label "macrogol" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainemadarosis
:madarosis rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_MedDRA_code 10051235 ;
           OpenPVSignal:has_MedDRA_prefered_term "Madarosis" ;
           rdfs:label "madarosis" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainemalaise
:malaise rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Adverse_Effect ;
         OpenPVSignal:has_MedDRA_code 10025482 ;
         OpenPVSignal:has_MedDRA_prefered_term "Malaise" ;
         rdfs:label "malaise" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainemedicalDeviceComplication
:medicalDeviceComplication rdf:type owl:NamedIndividual ,
                                    OpenPVSignal:Adverse_Effect ;
                           OpenPVSignal:has_MedDRA_code 10057281 ;
                           OpenPVSignal:has_MedDRA_prefered_term "Medical device complication" ;
                           rdfs:label "medical device complication" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainemedicationError
:medicationError rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Adverse_Effect ;
                 OpenPVSignal:has_MedDRA_code 10027091 ;
                 OpenPVSignal:has_MedDRA_prefered_term "Medication error" ;
                 rdfs:label "medication error" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainemedicineIneffective
:medicineIneffective rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_MedDRA_code 10013709 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Drug ineffective" ;
                     rdfs:label "medicine ineffective" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainemeloxicam
:meloxicam rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "M01AC06" ,
                                     "M01AC56" ;
           rdfs:label "meloxicam" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainemethadone
:methadone rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "N02AC52" ,
                                     "N07BC02" ;
           rdfs:label "methadone" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainemethotrexate
:methotrexate rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "L01BA01" ,
                                        "L04AX03" ;
              rdfs:label "methotrexate" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainemethylprednisolone
:methylprednisolone rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Drug ;
                    OpenPVSignal:has_ATC_code "D07AA01" ,
                                              "D07AC14" ,
                                              "D07CA02" ,
                                              "D10AA02" ,
                                              "H02AB04" ,
                                              "H02BX01" ,
                                              "S01CA08" ;
                    rdfs:label "methylprednisolone" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainemigraine
:migraine rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:refers_to_adverse_effect :headache ;
          OpenPVSignal:has_ICD_code "G43.911" ;
          OpenPVSignal:has_MedDRA_code 10027599 ;
          OpenPVSignal:has_MedDRA_prefered_term "Migraine" ;
          rdfs:label "migraine" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainemigraineAggravated
:migraineAggravated rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Adverse_Effect ;
                    OpenPVSignal:has_MedDRA_code 10027600 ;
                    OpenPVSignal:has_MedDRA_prefered_term "Migraine aggravated" ;
                    rdfs:label "migraine aggravated" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainemigraine_usage_for_ReportsWithDosageInformation_1
:migraine_usage_for_ReportsWithDosageInformation_1 rdf:type owl:NamedIndividual ,
                                                            OpenPVSignal:Drug_Usage ;
                                                   OpenPVSignal:refers_to_dosage :DosageOfGolimumab ;
                                                   OpenPVSignal:refers_to_drug :golimumab ;
                                                   rdfs:label "usage for reports with dosage info" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainemonthly
:monthly rdf:type owl:NamedIndividual ,
                  <http://www.w3.org/2006/time#DurationDescription> ;
         <http://www.w3.org/2006/time#nominalPosition> "months" ;
         <http://www.w3.org/2006/time#numericPosition> 1 ;
         rdfs:label "monthly" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainemuscle_strain
:muscle_strain rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Adverse_Effect ;
               OpenPVSignal:has_MedDRA_code 10050031 ;
               OpenPVSignal:has_MedDRA_prefered_term "Muscle strain" ;
               rdfs:label "muscle strain" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainemyalgia
:myalgia rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Adverse_Effect ;
         OpenPVSignal:has_MedDRA_code 10028411 ;
         OpenPVSignal:has_MedDRA_prefered_term "Myalgia" ;
         rdfs:label "myalgia" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineoedemaGeneralised
:oedemaGeneralised rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Adverse_Effect ;
                   OpenPVSignal:has_MedDRA_code 10030102 ;
                   OpenPVSignal:has_MedDRA_prefered_term "Oedema generalised" ;
                   rdfs:label "oedema generalised" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineoedemaPeripheral
:oedemaPeripheral rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Adverse_Effect ;
                  OpenPVSignal:has_MedDRA_code 10030124 ;
                  OpenPVSignal:has_MedDRA_prefered_term "Oedema peripheral" ;
                  rdfs:label "oedema peripheral" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineondansetron
:ondansetron rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "A04AA01" ;
             rdfs:label "ondansetron" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineopportunisticInfections
:opportunisticInfections rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Adverse_Effect ;
                         OpenPVSignal:has_MedDRA_code 10030901 ;
                         OpenPVSignal:has_MedDRA_prefered_term "Opportunistic infection" ;
                         rdfs:label "opportunistic infections" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineoralContraceptiveNos
:oralContraceptiveNos rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Drug ;
                      OpenPVSignal:has_ATC_code "G03A" ;
                      rdfs:label "oral contraceptive nos" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineosteoarthritis
:osteoarthritis rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Indication ;
                OpenPVSignal:has_MedDRA_code 10031161 ;
                OpenPVSignal:has_MedDRA_prefered_term "Osteoarthritis" ;
                rdfs:label "osteoarthritis" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainepainInExtremity
:painInExtremity rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Adverse_Effect ;
                 OpenPVSignal:has_MedDRA_code 10033425 ;
                 OpenPVSignal:has_MedDRA_prefered_term "Pain in extremity" ;
                 rdfs:label "pain in extremity" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainepantoprazole
:pantoprazole rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "A02BC02" ,
                                        "A02BD04" ,
                                        "A02BD11" ;
              rdfs:label "pantoprazole" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineparaesthesia
:paraesthesia rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_MedDRA_code 10033775 ;
              OpenPVSignal:has_MedDRA_prefered_term "Paraesthesia" ;
              rdfs:label "paraesthesia" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainepharyngitis
:pharyngitis rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_MedDRA_code 10034835 ;
             OpenPVSignal:has_MedDRA_prefered_term "Pharyngitis" ;
             rdfs:label "pharyngitis" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainephlebitis
:phlebitis rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_MedDRA_code 10034879 ;
           OpenPVSignal:has_MedDRA_prefered_term "Phlebitis" ;
           rdfs:label "phlebitis" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainepneumonia
:pneumonia rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_ICD_code "L29" ;
           OpenPVSignal:has_MedDRA_code 10035664 ;
           OpenPVSignal:has_MedDRA_prefered_term "Pneumonia" ;
           rdfs:label "pneumonia" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainepneumothorax
:pneumothorax rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_ICD_code "J93.9" ;
              OpenPVSignal:has_MedDRA_code 10035759 ;
              OpenPVSignal:has_MedDRA_prefered_term "Pneumothorax" ;
              rdfs:label "Pneumothorax" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineprednisolone
:prednisolone rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "A01AC54" ,
                                        "A07EA01" ,
                                        "C05AA04" ,
                                        "D07AA03" ,
                                        "D07BA01" ,
                                        "D07CA03" ,
                                        "D07XA02" ,
                                        "H02AB06" ,
                                        "R01AD02" ,
                                        "R01AD52" ,
                                        "S01BA04" ,
                                        "S01BB02" ,
                                        "S01CA02" ,
                                        "S01CB02" ,
                                        "S02BA03" ,
                                        "S02CA01" ,
                                        "S03BA02" ,
                                        "S03CA02" ,
                                        "V03AB05" ;
              rdfs:label "prednisolone" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineprednisone
:prednisone rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "A07EA03" ,
                                      "H02AB07" ;
            rdfs:label "prednisone" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainepruritus
:pruritus rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_MedDRA_code 10037087 ;
          OpenPVSignal:has_MedDRA_prefered_term "Pruritus" ;
          rdfs:label "pruritus" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainepsoriasis
:psoriasis rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Indication ;
           OpenPVSignal:has_MedDRA_code 10037153 ;
           OpenPVSignal:has_MedDRA_prefered_term "Psoriasis" ;
           rdfs:label "psoriasis" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainepsoriaticArthritis
:psoriaticArthritis rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Indication ;
                    OpenPVSignal:has_ICD_code " L40.52" ;
                    OpenPVSignal:has_MedDRA_code 10037162 ;
                    OpenPVSignal:has_MedDRA_prefered_term "psoriatic arthritis" ;
                    rdfs:label "psoriatic arthritis" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainepvSignal
:pvSignal rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Signal ;
          OpenPVSignal:Free_text_reporting_element :ConclusionContent ,
                                                   :DiscussionContent ,
                                                   :Introduction_content ,
                                                   :Migraine_pathology ,
                                                   :Reports_in_Vigibase ,
                                                   :SummaryContent ;
          OpenPVSignal:is_supported_by_individual_case_report :Report1 ,
                                                              :Report10 ,
                                                              :Report11 ,
                                                              :Report12 ,
                                                              :Report13 ,
                                                              :Report14 ,
                                                              :Report15 ,
                                                              :Report16 ,
                                                              :Report17 ,
                                                              :Report18 ,
                                                              :Report19 ,
                                                              :Report2 ,
                                                              :Report20 ,
                                                              :Report21 ,
                                                              :Report22 ,
                                                              :Report3 ,
                                                              :Report4 ,
                                                              :Report5 ,
                                                              :Report6 ,
                                                              :Report7 ,
                                                              :Report8 ,
                                                              :Report9 ;
          OpenPVSignal:is_supported_by_statistical_entity :OverallReportsForAdalimumabAndMigraine ,
                                                          :OverallReportsForCertolizumab ,
                                                          :OverallReportsForEtanerceptAndMigraine ,
                                                          :OverallReportsForInfiximabAndMigraine ,
                                                          :OverallReportsWithGolimumabAndMigraine ,
                                                          :ReportsWithAS ,
                                                          :ReportsWithDosageInformation ,
                                                          :ReportsWithGolimumabAsTheOnlyDrugSuspected ,
                                                          :ReportsWithNoRecoveryAsOutcome ,
                                                          :ReportsWithNoRecoveryAsOutcomeAndDechallenge ,
                                                          :ReportsWithPsoriasis ,
                                                          :ReportsWithRecoveryAsOutcome ,
                                                          :ReportsWithRecoveryAsOutcomeAndDechallenge ,
                                                          :ReportsWithRheumatoidArthritis ,
                                                          :ReportsWithScAdministrationOfGolimumab ,
                                                          :ReportsWithTimeToOnsetAsInformation ,
                                                          :Reports_from_Australia ,
                                                          :Reports_from_Canada ,
                                                          :Reports_from_Denmark ,
                                                          :Reports_from_Sweden ,
                                                          :Reports_from_Switzerland ,
                                                          :Reports_from_UK ,
                                                          :Reports_from_US ,
                                                          :Reports_with_age_info ,
                                                          :Reports_with_fatigue ,
                                                          :Reports_with_headache ,
                                                          :Reports_with_hypoaesthesia ,
                                                          :Reports_with_paraestesia ,
                                                          :Reports_with_vision_abnormal ,
                                                          :Reports_with_vomiting ,
                                                          :incidence_in_men ,
                                                          :incidence_in_women ,
                                                          <http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraine#ReportsRA/osteoarthritis> ,
                                                          <http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraine#ReportsWithRA/PsA> ;
          OpenPVSignal:refers_to_adverse_effect :migraine ;
          OpenPVSignal:refers_to_drug :golimumab ;
          OpenPVSignal:refers_to_primary_suspect_drug :golimumab ;
          mp:supportedByData :GolimumabAndAutoimmunieProcess ,
                             :GolimumabAndBalanceDisorders ,
                             :GolimumabAndCongestiveHeartFailure ,
                             :GolimumabAndDemyelinatingDisorders ,
                             :GolimumabAndDizziness ,
                             :GolimumabAndDysgeusia ,
                             :GolimumabAndHaematologicalReactions ,
                             :GolimumabAndHeadache ,
                             :GolimumabAndHepatitisBVirusReactivation ,
                             :GolimumabAndLymphoma ,
                             :GolimumabAndParaesthesia ,
                             :GolimumabAndSeriousInfections ,
                             :Migraine_and_adalimumab ,
                             :Migraine_and_certolizumab ,
                             :TNF-aInhibitorsAndMigraine ,
                             :TimeToOnsetForGolimumabAndMigraine ,
                             :d ;
          OpenPVSignal:initially_identified_on "01/05/2015" ;
          rdfs:label "pv signal" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainepyrexia
:pyrexia rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Adverse_Effect ;
         OpenPVSignal:has_MedDRA_code 10037660 ;
         OpenPVSignal:has_MedDRA_prefered_term "Pyrexia" ;
         rdfs:label "pyrexia" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainepyridoxine
:pyridoxine rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "A11HA02" ;
            rdfs:label "pyridoxine" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainerash
:rash rdf:type owl:NamedIndividual ,
               OpenPVSignal:Adverse_Effect ;
      OpenPVSignal:has_MedDRA_code 10037844 ;
      OpenPVSignal:has_MedDRA_prefered_term "Rash" ;
      rdfs:label "rash" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainerashErythematous
:rashErythematous rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Adverse_Effect ;
                  OpenPVSignal:has_ICD_code "A41" ;
                  OpenPVSignal:has_MedDRA_code 10037855 ;
                  OpenPVSignal:has_MedDRA_prefered_term "Rash erythematous" ;
                  rdfs:label "rash erythematous" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainerheumatoidArthritis
:rheumatoidArthritis rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Indication ;
                     OpenPVSignal:has_ICD_code "M06.9" ;
                     OpenPVSignal:has_MedDRA_code 10039073 ;
                     OpenPVSignal:has_MedDRA_prefered_term "rheumatoid arthritis" ;
                     rdfs:label "rheumatoid arthritis" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainerhinitis
:rhinitis rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_MedDRA_code 10039083 ;
          OpenPVSignal:has_MedDRA_prefered_term "Rhinitis" ;
          rdfs:label "rhinitis" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainerizatriptan
:rizatriptan rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "N02CC04" ;
             rdfs:label "rizatriptan" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainesalbutamol
:salbutamol rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "R03AC02" ,
                                      "R03AK04" ,
                                      "R03AL02" ,
                                      "R03CC02" ;
            rdfs:label "salbutamol" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainesepsis
:sepsis rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Adverse_Effect ;
        OpenPVSignal:has_MedDRA_code 10040047 ;
        OpenPVSignal:has_MedDRA_prefered_term "Sepsis" ;
        rdfs:label "sepsis" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainesinusitis
:sinusitis rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_MedDRA_code 10040753 ;
           OpenPVSignal:has_MedDRA_prefered_term "Sinusitis" ;
           rdfs:label "sinusitis" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineskinDisorders
:skinDisorders rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Adverse_Effect ;
               OpenPVSignal:has_MedDRA_code 10040831 ;
               OpenPVSignal:has_MedDRA_prefered_term "Skin disorder" ;
               rdfs:label "skin disorders" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainespeechDisorder
:speechDisorder rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Adverse_Effect ;
                OpenPVSignal:has_MedDRA_code 10041466 ;
                OpenPVSignal:has_MedDRA_prefered_term "Speech disorder" ;
                rdfs:label "speech disorder" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainespironolactone
:spironolactone rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Drug ;
                OpenPVSignal:has_ATC_code "C03DA01" ;
                rdfs:label "spironolactone" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainesubcutaneousTissueDisorders
:subcutaneousTissueDisorders rdf:type owl:NamedIndividual ,
                                      OpenPVSignal:Adverse_Effect ;
                             OpenPVSignal:has_MedDRA_code 10040785 ;
                             OpenPVSignal:has_MedDRA_prefered_term "Skin and subcutaneous tissue disorders" ;
                             rdfs:label "subcutaneous tissue disorders" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainesulfasalazine
:sulfasalazine rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Drug ;
               OpenPVSignal:has_ATC_code "A07EC01" ,
                                         "G01AE10" ;
               rdfs:label "sulfasalazine" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainesumatriptan
:sumatriptan rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "G01AE10" ,
                                       "N02CC01" ;
             rdfs:label "sumatriptan" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainesuperficialFungalInfections
:superficialFungalInfections rdf:type owl:NamedIndividual ,
                                      OpenPVSignal:Adverse_Effect ;
                             OpenPVSignal:has_MedDRA_code 10017543 ;
                             OpenPVSignal:has_MedDRA_prefered_term "Fungal skin infection" ;
                             rdfs:label "superficial fungal infections" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainetacrolimus
:tacrolimus rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "D11AH01" ,
                                      "L04AD02" ;
            rdfs:label "tacrolimus" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineteriparatide
:teriparatide rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "H05AA02" ;
              rdfs:label "teriparatide" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainetherapeuticResponseIncreased
:therapeuticResponseIncreased rdf:type owl:NamedIndividual ,
                                       OpenPVSignal:Adverse_Effect ;
                              OpenPVSignal:has_MedDRA_code 10043415 ;
                              OpenPVSignal:has_MedDRA_prefered_term "Therapeutic response increased" ;
                              rdfs:label "therapeutic response increased" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainetopirimate
:topirimate rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "N03AX11 " ;
            rdfs:label "topirimate" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainetuberculosis
:tuberculosis rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_MedDRA_code 10044755 ;
              OpenPVSignal:has_MedDRA_prefered_term "Tuberculosis" ;
              rdfs:label "tuberculosis" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineulcerativeColitis
:ulcerativeColitis rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Indication ;
                   OpenPVSignal:has_ICD_code "K51" ;
                   OpenPVSignal:has_MedDRA_code 10009900 ;
                   OpenPVSignal:has_MedDRA_prefered_term "Colitis ulcerative" ;
                   rdfs:label "ulcerative colitis " .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineupperRespiratoryTractInfection
:upperRespiratoryTractInfection rdf:type owl:NamedIndividual ,
                                         OpenPVSignal:Adverse_Effect ;
                                OpenPVSignal:has_MedDRA_code 10046306 ;
                                OpenPVSignal:has_MedDRA_prefered_term "Upper respiratory tract infection" ;
                                rdfs:label "upper respiratory tract infection" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineviralInfections
:viralInfections rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Adverse_Effect ;
                 OpenPVSignal:has_MedDRA_code 10047461 ;
                 OpenPVSignal:has_MedDRA_prefered_term "Viral infection" ;
                 rdfs:label "viral infections" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainevisionAbnormal
:visionAbnormal rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Adverse_Effect ;
                OpenPVSignal:has_MedDRA_code 10047508 ;
                OpenPVSignal:has_MedDRA_prefered_term "Vision abnormal" ;
                rdfs:label "vision abnormal" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainevisualAbnormal
:visualAbnormal rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Adverse_Effect ;
                OpenPVSignal:has_MedDRA_code 10047508 ;
                OpenPVSignal:has_MedDRA_prefered_term "Vision abnormal" ;
                rdfs:label "visual abnormal" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainevitamins
:vitamins rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Drug ;
          OpenPVSignal:has_ATC_code "A11" ;
          rdfs:label "vitamins" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainevitaminsNos
:vitaminsNos rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "A12" ;
             rdfs:label "vitamins nos" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainevomiting
:vomiting rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_MedDRA_code 10047700 ;
          OpenPVSignal:has_MedDRA_prefered_term "Vomiting" ;
          rdfs:label "vomiting" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraineweight_decrease
:weight_decrease rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Adverse_Effect ;
                 OpenPVSignal:has_MedDRA_code 10047893 ;
                 OpenPVSignal:has_MedDRA_prefered_term "Weight decrease" ;
                 rdfs:label "weight decrease" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migrainezolpidem
:zolpidem rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Drug ;
          OpenPVSignal:has_ATC_code "N05CF02" ;
          rdfs:label "zolpidem" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraine#A/H1N1InfluenzaPandemicVaccine
<http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraine#A/H1N1InfluenzaPandemicVaccine> rdf:type owl:NamedIndividual ,
                                                                                                         OpenPVSignal:Drug ;
                                                                                                OpenPVSignal:has_ATC_code "J07BB" ;
                                                                                                rdfs:label "A/H1N1 Influenza pandemic vaccine" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraine#ReportsRA/osteoarthritis
<http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraine#ReportsRA/osteoarthritis> rdf:type owl:NamedIndividual ,
                                                                                                   OpenPVSignal:Reports_group ;
                                                                                          OpenPVSignal:concerns_indication_for_use :osteoarthritis ,
                                                                                                                                   :rheumatoidArthritis ;
                                                                                          OpenPVSignal:is_subgroup_of :OverallReportsWithGolimumabAndMigraine ;
                                                                                          OpenPVSignal:has_count 1 ;
                                                                                          OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                                                                          rdfs:label "Reports with RA/osteoarthritis" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraine#ReportsWithRA/PsA
<http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraine#ReportsWithRA/PsA> rdf:type owl:NamedIndividual ,
                                                                                            OpenPVSignal:Reports_group ;
                                                                                   OpenPVSignal:concerns_indication_for_use :psoriaticArthritis ,
                                                                                                                            :rheumatoidArthritis ;
                                                                                   OpenPVSignal:is_subgroup_of :OverallReportsWithGolimumabAndMigraine ;
                                                                                   OpenPVSignal:has_count 1 ;
                                                                                   OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                                                                   rdfs:label "Reports with RA/PsA" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraine#ergocalciferol/calciumphosphate/calciumSodiumLactate
<http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraine#ergocalciferol/calciumphosphate/calciumSodiumLactate> rdf:type owl:NamedIndividual ,
                                                                                                                               OpenPVSignal:Drug ;
                                                                                                                      OpenPVSignal:has_ATC_code "A11CC01" ,
                                                                                                                                                "A12AA01" ;
                                                                                                                      rdfs:label "ergocalciferol/calcium phosphate/calcium sodium lactate" .


###  http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraine#ethinylestradiol/desogestrel
<http://purl.org/OpenPVSignal/Signals/2015_2_golimumab_migraine#ethinylestradiol/desogestrel> rdf:type owl:NamedIndividual ,
                                                                                                       OpenPVSignal:Drug ;
                                                                                              OpenPVSignal:has_ATC_code "G03AB05" ;
                                                                                              rdfs:label "ethinylestradiol/desogestrel" .


###  Generated by the OWL API (version 4.5.9.2019-02-01T07:24:44Z) https://github.com/owlcs/owlapi
